Extraordinary General Meeting held in DiaGenic ASA

An extraordinary general meeting of DiaGenic ASA was held on 22 November 2013.

All proposals set out in the notice to the general meeting were approved.

Please find minutes from the extraordinary general meeting attached. The minutes will also be posted on www.newsweb.no and www.diagenic.com

Contact:

Hanne S. Holen, Chairman

Telephone: +47 982 94 591

E-mail: hanne.s.holen@adeb.no

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com